{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T10:52:43Z","timestamp":1761562363598},"reference-count":5,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2018,4,5]],"date-time":"2018-04-05T00:00:00Z","timestamp":1522886400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1007\/s00262-018-2159-3","type":"journal-article","created":{"date-parts":[[2018,4,5]],"date-time":"2018-04-05T11:15:57Z","timestamp":1522926957000},"page":"1325-1327","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Immune-mediated cholangitis: is it always nivolumab\u2019s fault?"],"prefix":"10.1007","volume":"67","author":[{"given":"Francesco","family":"Gelsomino","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Vitale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Ardizzoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,4,5]]},"reference":[{"key":"2159_CR1","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s00262-017-2062-3","volume":"67","author":"J Kashima","year":"2018","unstructured":"Kashima J, Okuma Y, Shimizuguchi R, Chiba K (2018) Bile duct obstruction in a patient treated with nivolumab as second-line chemotherapy for advanced non-small-cell lung cancer: a case report. Cancer Immunol Immunother 67:61\u201365. \n                    https:\/\/doi.org\/10.1007\/s00262-017-2062-3","journal-title":"Cancer Immunol Immunother"},{"key":"2159_CR2","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/s10637-017-0453-0","volume":"35","author":"H Kawakami","year":"2017","unstructured":"Kawakami H, Tanizaki J, Tanaka K et al (2017) Imaging and clinicopathological features of nivolumab-related cholangitis in patients with non-small cell lung cancer. Invest New Drugs 35:529\u2013536","journal-title":"Invest New Drugs"},{"key":"2159_CR3","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1093\/annonc\/mdx422.005","volume":"28","author":"F Gelsomino","year":"2017","unstructured":"Gelsomino F, Vitale G, D\u2019Errico A, Bertuzzi C, Andreone P, Ardizzoni A (2017) Nivolumab-induced cholangitic liver disease: a novel form of serious liver injury. Ann Oncol 28:671\u2013672","journal-title":"Ann Oncol"},{"key":"2159_CR4","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.jhep.2009.04.009","volume":"51","author":"European Association for the Study of the Liver","year":"2009","unstructured":"European Association for the Study of the Liver (2009) EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol 51:237\u2013267","journal-title":"J Hepatol"},{"issue":"suppl_4","key":"2159_CR5","doi-asserted-by":"publisher","first-page":"iv119-iv142","DOI":"10.1093\/annonc\/mdx225","volume":"28","author":"JBAG Haanen","year":"2017","unstructured":"Haanen JBAG., Carbonnel F, Robert C, Kerr KM, Peters S, Larkin J, Jordan K, ESMO Guidelines Committee (2017) Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 28(suppl_4):iv119-iv142","journal-title":"Ann Oncol"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00262-018-2159-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-018-2159-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-018-2159-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,5]],"date-time":"2019-04-05T16:00:39Z","timestamp":1554480039000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00262-018-2159-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,5]]},"references-count":5,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["2159"],"URL":"https:\/\/doi.org\/10.1007\/s00262-018-2159-3","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,5]]},"assertion":[{"value":"3 February 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}